Satoshi Yamashita

Mr. Satoshi Yamashita

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAtsuhisa Sato
Atsuhisa Sato
DRDaloha Rodriguez-Molina
Daloha Rodriguez-Molina
KYKanae Yoshikawa-Ryan
Kanae Yoshikawa-Ryan
SYSatoshi Yamashita
Satoshi Yamashita
SOSuguru Okami
Suguru Okami
DVDavid Vizcaya
David Vizcaya
Background: In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence regarding finerenone use in real-world settings is limited. Methods: A retrospective cohort study (NCT06278207) using two Japanese nationwide hospital-based databases provided by Medical Data Vision (MDV) and Real World Data Co., Ltd. (RWD Co., Kyoto Japan), converted to the OMOP common data model, was conducted. Persons with CKD and T2D initiating finerenone from 1 July 2021, to 30 August 2023, were included. Baseline characteristics were described. The occurrence of hyperkalemia after finerenone initiation was assessed. Results: 1029 new users of finerenone were included (967 from MDV and 62 from RWD Co.). Mean age was 69.5 and 72.4 years with 27.3% and 27.4% being female in the MDV and RWD Co. databases, respectively. Hypertension (92 and 95%), hyperlipidemia (59 and 71%), and congestive heart failure (60 and 66%) were commonly observed comorbidities. At baseline, 80% of persons were prescribed angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers. Sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists were prescribed in 72% and 30% of the study population, respectively. The incidence proportions of hyperkalemia were 2.16 and 2.70 per 100 persons in the MDV and RWD Co. databases, respectively. There were no hospitalizations associated with hyperkalemia observed in either of the two datasets. Conclusions: For the first time, we report the largest current evidence on the clinical use of finerenone in real-world settings early after the drug authorization in Japan. This early evidence from clinical practice suggests that finerenone is used across comorbidities and comedications.

18 September 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
RARajiv Agarwal
Rajiv Agarwal
JGJennifer B. Green
Jennifer B. Green
HHHiddo Heerspink
Hiddo Heerspink
JMJohannes F.E. Mann
Johannes F.E. Mann
JMJanet B. McGill
Janet B. McGill
MNMasaomi Nangaku
Masaomi Nangaku
Key Points: Finerenone plus empagliflozin was more effective in reducing urinary albumin-to-creatinine ratio than either drug alone in Asian participants of the CONFIDENCE trial. Except for hyperkalemia, adverse events and serious adverse events were less frequent in participants from Asia than in the overall CONFIDENCE trial population. The risk–benefit profile of the combination seems similarly favorable in people from Asia as in the overall CONFIDENCE trial population. Background: The COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a urinary albumin-to-creatinine ratio (UACR) Endpoint (CONFIDENCE) trial compared simultaneous initiation of finerenone with empagliflozin versus either drug alone. We report a pre-specified participant-level exploratory analysis of outcomes in the subpopulation from Asia (India, Japan, the Republic of Korea, and Taiwan). Methods: Adults with CKD and type 2 diabetes with UACR between 100 and 5000 mg/g and on a renin–angiotensin system inhibitor were recruited. Participants were randomized 1:1:1 to 180 days of treatment with finerenone 10/20 mg once daily (and empagliflozin-matching placebo), empagliflozin 10 mg once daily (and finerenone-matching placebo), or a combination of both. The primary efficacy outcome was change from baseline in UACR at 180 days. Safety and tolerability were also assessed. Results: This analysis included 360 participants from Asia. At day 180, the reduction in UACR with combination therapy was 30% greater than that with finerenone alone (95% confidence interval [CI], 12% to 45%; P = 0.003) and 34% greater than that with empagliflozin alone (95% CI, 16% to 47%; P < 0.001). In general, adverse and serious adverse events were numerically less common in participants from Asia than in those from Europe/North America, except for hyperkalemia. Investigator-reported (10% versus 7%) and laboratory-assessed hyperkalemia (serum potassium >5.5 mmol/L; 19% versus 11%) were more frequent in participants from Asia; however, eGFR declines of >30% at day 30 were less frequent in Asia (3% versus 5%). Conclusions: Simultaneous initiation of finerenone and empagliflozin was effective and well tolerated among CONFIDENCE study participants from Asia, consistent with the overall population.